Leadership briefing
The Global Network Effect in Biotech: Leen Kawas’ Perspective
A promising compound can die in a lab not because the science failed but because the right collaborator never appeared. Biotech, more than most industries, depends on connections that cross institutions, countries, and disciplines, since no single lab or company holds every piece of expertise a discovery needs to become a treatment. Leen Kawas, a scientist and entrepreneur who serves as CEO of EIT Pharma and sits on the board of Inherent Biosciences, has built a career around understanding that dependency, as she has explained elsewhere.
Discovery Rarely Happens in Isolation
The image of a lone scientist making a breakthrough discovery in an isolated lab is mostly a myth, and biotech makes that myth harder to sustain than almost any other field. A molecule identified in one lab needs formulation expertise that may sit in a different institution, needs clinical trial infrastructure that requires yet another set of partners, and needs regulatory expertise that varies significantly across jurisdictions. Kawas’ path, which included co-founding and leading Athira Pharma through late-stage clinical programs and a 2020 public offering that raised over four hundred million dollars, making her one of only twenty-two women founders in the US to do so, required exactly this kind of coordination across a wide network of collaborators.
That achievement is worth pausing on for what it reveals about the underlying mechanics of biotech success. Leen Kawas’s approach to cross-border collaboration shows that taking a company public at that scale is not a solo accomplishment. It requires trust built across scientific advisors, financial partners, regulatory consultants, and clinical investigators, often spread across continents, all aligned around a shared conviction that the underlying science was worth the sustained investment.
Why Cross-Border Relationships Matter More in Biotech
Biotech innovation does not respect national borders, partly because the scientific talent pool is genuinely global and partly because the regulatory and funding landscape varies enough between countries that a company often needs relationships in multiple jurisdictions to move a program forward efficiently. A single-country network limits a company to whatever expertise and capital happen to exist within that country’s borders, which is a real constraint given how specialized modern drug development has become.
Kawas’ current work, including her EIT Pharma leadership and her role as co-founder and managing general partner of Propel Bio Partners, a biotech-focused venture fund supporting life science innovation, reflects an approach built around expanding that network rather than working within a narrower, geographically limited one. A venture fund focused on life sciences is, in effect, a mechanism for connecting capital to scientific opportunity across a wider field than any single founder or company could access alone.
Cross-border relationships also shape which risks a founder is willing to take on. A company confident it can draw on scientific advisors in one country and manufacturing partners in another can pursue a more ambitious program than a company confined to whatever talent happens to exist locally. That confidence is not abstract. It rests on relationships built over years, tested through smaller collaborations before a founder trusts them with a program that could define a company’s future.
The Board Seat as a Network Node
Serving on the board of Inherent Biosciences places Kawas in a position to extend that network effect beyond her own ventures. Board members bring more than oversight, they bring access to relationships built over an entire career, connections to potential collaborators, later-stage investors, and scientific advisors that a growing company might not otherwise reach on its own timeline. That access can matter as much as the specific guidance offered in any single board meeting.
This is a subtler form of the network effect than a formal partnership or licensing deal, but it may be just as consequential over time. A board member who has personally navigated the path from early discovery to public offering carries pattern recognition that a company still finding its footing has not yet had the chance to develop on its own.
Companies that treat a board seat as a formality, filling it for governance requirements rather than strategic value, miss this dimension entirely. The seat becomes a checkbox rather than an active channel through which relationships and early warnings flow back into the company at moments when a founder deep in day-to-day operations might otherwise miss them. Further background is available at https://leenkawas.me/.
What the Network Actually Produces
The value of a global network in biotech is not simply that it feels more prestigious to have international connections. It is that the network directly determines which discoveries survive the journey from lab bench to patient. A compound with genuine therapeutic potential can still fail to reach patients if the founder cannot connect it to the clinical infrastructure and regulatory expertise required to advance it, regardless of how promising the underlying science is.
Leen Kawas’ career, spanning company leadership, venture investment, and board governance, suggests a consistent belief that no single node in that network is sufficient alone, as covered in this profile. The scientist needs the investor. The investor needs the regulatory expert. The regulatory expert needs the clinical infrastructure. Understanding that interdependence, and building the relationships to act on it, is what separates a promising discovery from an approved treatment.